A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID | MicrobiomeTrials
A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-07-15Est. Completion: 2026-12-01
Enrollment target: 252 participants
Locations
University of Arizona, Tucson, Arizona, United States